Login
Companies $AMLX
$27.67 -$0.13 (0.47%) After hours
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc.

amylyx.com

What Do They Do?

Develops investigational drug treatments for people with endocrine conditions and neurodegenerative diseases, including post-bariatric hypoglycemia, Wolfram syndrome and ALS.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −32% (Loss)
vs −$34.4M in Q3 FY2025

Commercial sales ended The earlier report described RELYVRIO and ALBRIOZA as marketed ALS treatments. The latest describes Amylyx as clinical-stage and says it discontinued those products and does not expect further sales revenue.

Broader disease focus The earlier report centered on a marketed ALS treatment and neurodegenerative diseases; the latest also describes endocrine programs for post-bariatric hypoglycemia and Wolfram syndrome.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support